1. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22(42): 6549-56.
2. Fam PN, Verma S, Kutryk M, Stewart JD. Clinician Guide to Angiogenesis. Circulation 2003; 108(21): 2613-8.
3. Kirsch M, Schackert G, Black PM. Metastasis and angiogenesis. Cancer Treat Res 2004; 117: 285-304.
4. Folkman J. Tumor Angiogenesis Factor. Cancer Res 1974; 34: 2109-13.
5. Conway EM, Collen D, Carmeliet P. Molecular

1. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry(Mosc) 2008; 73(7): 751-62.
2. Ucuzian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. J Burn Care Res 2010; 31(1): 158-75.
3. Ruhrberg C. Endogenous inhibitors of angiogenesis. J Cell Sci 2001; 14: 3215-6.
4. Martinez A. A new family of angiogenic factors. Cancer Lett 2006; 236: 157-63.
5. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013; 123(8): 3190-200.
6. De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med 2014; 29(1): 1-11.
7. Arshi A, Ghahramani Seno MM, Ansari H, Doosti A, Khoramian M, Sazgar H. Comparison of GAS5 Long non-coding RNA Expression and NEAT1 in Breast Cancer Patients and Healthy People. Armaghane Danesh 2016; 21(3): 278-89. [Article in Farsi]
8. Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul) 2014; 22(1): 1-9.
9. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9(10): 919-25.
10. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 428(7070): 967-74.
11. Keane MP, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis. Chem Immunol 1999; 72: 86-101.
12. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling-in controlof vascular function. Nature Rev 2006; 7: 359-69.
13. Stepien HM, Kołomecki K, Pasieka Z, Komorowski J, Stepień T, Kuzdak K. Angiogenesis of endocrine gland tumours--new molecular targets in diagnostics and therapy. Eur J Endocrinol 2002; 146(2): 143-51.
14. Mozaffari  E,  Doosti     A,    Arshi    A,   Faghani   M.

1. Mozaffari E, Doosti A, Nemati R, Faghani M, Arshi A, Makhlooei M. Association of COX-2-765G→C Gene Polymorphism and Migraine in Iranian Populations. Inter J Rev in Life Sci 2015; 5(8): 232-8.
2. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 19(473): 298-307.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-49.
3. Bielenberg DR, D Amore PA, Judah Folkman S. Contribution to the inhibition of angiogenesis. Lymph Res Biol 2008; 6: 203-7.
4. Ruegg C. Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol 2006; 80(4): 682-4.
5. Pandya N, Dhalla N, Santani D. Angiogenesis--a new target for future therapy. Vascul Pharmacol 2006; 44(5): 265-74.
6. Dudley A, Cloer E, Melero-Martin J. The Role of Bone Marrow-Derived Progenitor Cells in Tumor Growth and Angiogenesis. Stem Cells and Cancer Stem Cells 2012; 8: 45-54.
7. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010; 126(9): 2090-101.
8. Plate K, Scholz S, Dumont D. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 2012; 124: 763-75.
9. Welch-Reardon KM, Ehsan SM, Wang K, Wu N, Newman AC, Romero-Lopez M, et al. Angiogenic sprouting is regulated by endothelial cell expression of Slug (Snai2). J Cell Sci 2014; 127(Pt 9): 2017-28.
10. Ricci-Vitiani L, Pallini R, Biffoni M. Tumour vas-cularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468(7325): 824-8.
11. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancertherapy. Eur J Cancer 2006; 42(6): 717-27.
12. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012; 320(2): 130-7.
13. Carmeliet  P.     Mechanisms    of   angiogenesis   and

1. Bauer MS, Bauer JR, Velazquez CO. Angiogenesis, Vasculogenesis, and Induction of Healing in Chronic Wounds. Vasc Endovascular Surg 2005; 39(4): 293-306.
2. Carramolino L, Fuentes J, García-Andrés J, Azcoitia V, Riethmacher D, Torres M. Platelets Play an Essential Role in Separating the Blood and Lymphatic Vasculatures During Embryonic Angiogenesis. Circ Res 2010; 106(7): 1197-201.
3. Semenza LG. Vasculogenesis, Angiogenesis, and Arteriogenesis: Mechanisms of Blood Vessel Formation and Remodeling. J Cell Biochem 2007; 102(4): 840-7.
4. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch 2009; 457(5): 963-77.
5. Baharara J, Zafar-Balannezhad S, Shahrokh Abadi KH, Hesami Z. Synergic effects of Atorvastatin and low frequency electromagnetic field on chorioallantoic membrane angiogenesis of chick embryo. J Birjand Univ Med Sci 2012; 19(1): 148-56. [Article in Farsi]
6. Mousavi M, Baharara J, Zafar-Balanezhad S, Shaheokh-Abadi Kh. The Effect of Saffron Aqua Extract on Angiogenesis in Chick Chorioalantoic. Zahedan J Res Med Sci 2014; 16(3): 55-8. [Article in Farsi]
7. Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U, et al. Estrogen-Mediated Angiogenesis in Thyroid Tumor Microenvironment Is Mediated Through VEGF Signaling Pathways. Arch Otolaryngol Head Neck Surg 2011; 137(11): 1146-53.
8. Baharara J, Zafar-Balanezhad S, Nejad-Shahrokhabadi Kh. The effects of different doses of atorvastatin on angiogenesis of chorioallantoic membrane of chick embryo. J Shahrekord Univ Med Sci 2012; 14(2): 82-9. [Article in Farsi]
9. Li WW, Li VW, Hutnik M, Chiou AS. Tumor Angiogenesis as a Target for Dietary Cancer Prevention. J Oncol 2012; 2012: 879623.
10. Cascone TV, Heymach J. Targeting the
    Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels with a Double-Edged Sword. J Clin Oncol 2012; 30(4): 441-4.
11. Giancotti F. Mechanisms Governing Metastatic Dormancy and Reactivation. Cell 2013; 155(4): 750-64.
12. Laporte L, Rieux A, Tuinstra M, Zelivyanskaya L. Vascular endothelial growth factor and fibroblast growth factor 2 delivery from spinal cord bridges to enhance  angiogenesis   following  injury. J  Biomed

1. Rivera L, Pandika M, Bergers G. Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell’s Perspective. Adv Exp Med Biol 2013; 772: 83-99.
2. Gerald D, Chintharlapalli SG, Augustin HE, Benjamin L. Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy. Cancer Res 2013; 73(6): 1649-57.
3. Zafar-Balanezhad S, Parivar k, Baharara J, Mohseni-Koochesfahani H, Ashraf A. The synergistic effects of sodium valproate and extremely low frequency electromagnetic field on angiogenesis. Scientific Research and Essays 2011; 6(1): 1-5.
4. Mossavi M, Baharara J, Zafar-Balannezhad S, Shahrokh Abadi KH. The synergic effects of Saffron aqua extract and low frequency electromagnetic field on angiogenesis in chick chorioalantoic membrane. J Shahrekord Univ Med Sci 2013; 15(1): 1-10. [Article in Farsi]
5. Mostafaie A, Mohammadi Motlagh MR, Mansouri K. Angiogenesis and the Models to Study Angiogenesis. Yakhteh Medical Journal 2010; 11: 374-81. [Article in Farsi]
6. Somasundaram C, Nath R, Bukoski R, Diz D. Identification and Characterization of Novel Perivascular Adventitial Cells in the Whole Mount Mesenteric Branch Artery Using Immunofluorescent Staining and Scanning Confocal Microscopy Imaging. Int J Cell Biol 2012: 2012: 172746.
7. Ruoslahti E. Specialization of tumour vasculature. Nature Reviews Cancer 2002; 2: 83-90.

 
 

 

 

Angiogenesis: A Review of Molecular Mechanism
 
Roozbahani M.¹, Jamshidian H.^2,3, Mahmoudi E.³, Arshi A.^4
 
 
1School of Basic Sciences, Islamic Azad University of Shahrekord Branch, Shahrekord, Iran
²Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
²Isfahan Regional Educational Blood Transfusion Center, Isfahan, Iran
³Biotechnology Research Center, Islamic Azad University of Shahrekord Branch, Shahrekord, Iran
⁴Young Researchers and Elite Club, Najafabad Branch, Islamic Azad University, Najafabad, Iran
 
 
Abstract
Background and Objectives
Angiogenesis is the formation of new blood vessels from pre-existing ones. Angiogenesis is an important event in a variety of physiological processes such as embryonic development, menstrual cycles, reproduction, and wound repair. It is also involved in pathological conditions such as solid tumors, diseases of the eye, diabetic retinopathy and nephropathy, hypertension psoriasis, endometriosis and obesity. Angiogenesis is dependent on a delicate equilibrium between endogenous angiogenic and antiangiogenic factors.
 
Materials and Methods
Because of the angiogenesis importance in the development of its dependent diseases, in this Review article we examined the different dimensions of the angiogenesis process, mechanisms and factors. The data were extracted from NCBI and SID.
 
Results
Angiogenesis has driven by a cocktail of growth factors and pro-angiogenic cytokines and is tempered by an equally diverse group of inhibitors of neovascularization based on recent work from several laboratories; it is now eminently clear that angiogenesis and unrestricted production of normal or aberrant forms of pro-angiogenic mediators but also the result of a relative deficiency in angiogenic-inhibitory molecules. In general, the process of angiogenesis is a multi-factorial and highly structured sequence of cellular events comprising migration, proliferation and differentiation of endothelial cells and finally vascular formation, maturation and remodeling
 
Conclusions 
The key factor that regulates proliferation and migration of endothelial cells is the Vascular Endothelial Growth Factor (VEGF). Angiogenic therapy includes inhibition of abnormal angiogenesis in some conditions such as tumors and stimulation of angiogenesis in conditions of ischemia, such as in ischemic heart disease or peripheral vascular disease.
 
Key words: Pathology, VEGF, Blood Vessels
 
 
Received: 28 Aug 2017
Accepted:   9 Jan 2018
 
 

Correspondence: Arshi A., MSc in Genetics. Young Researchers and Elite Club, Najafabad Branch, Islamic Azad  University.
P.O.Box: 517, Isfahan, Iran. Tel: (+9831) 32607071; Fax: (+9831) 32607071
E-mail: